Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. The stock increased 0.62% or $0.85 on November 22, reaching $138.04.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Patrick G. Enright sold 352 shares of the business's stock in a transaction that occurred on Friday, November 17th. It has underperformed by 15.45% the S&P500. Hedge funds and other institutional investors own 90.52% of the company's stock. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company's stock worth $257,000 after acquiring an additional 400 shares during the last quarter. The stock increased 1.18% or $3.01 on November 22, reaching $258.69. About shares traded. Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ) has risen 1.25% since November 23, 2016 and is uptrending. It has outperformed by 37.08% the S&P500. Its down 0.31, from 1.55 in 2017Q1. Endurant Ltd Partnership invested in 2.62% or 59,600 shares. 41 funds opened positions while 92 raised stakes. Highbridge Cap Mgmt invested 0.07% in Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ). (NYSE:BIO). Invesco Ltd holds 0% or 65,938 shares. Brave Asset Incorporated stated it has 1,660 shares. 232,518 were accumulated by Polar Capital Ltd Liability Partnership. Ent Serv Corporation invested in 154 shares. Tdam Usa stated it has 4,345 shares or 0.03% of all its holdings. Wells Fargo And Company Mn invested in 0.02% or 497,430 shares.
Tekla Capital Management Llc increased Ultragenyx Pharmaceutical Inc.
More notable recent Bio-Rad Laboratories, Inc. They issued a "buy" rating and a $206.00 target price on the stock. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have issued a buy rating to the stock. Therefore 76% are positive.
A number of research analysts have issued reports on the company. The rating was maintained by Jefferies on Thursday, June 8 with "Buy". The company was initiated on Thursday, October 13 by CL King. Morgan Stanley initiated the shares of JAZZ in report on Thursday, October 5 with "Hold" rating. The stock of Bio-Rad Laboratories, Inc. The firm has "Buy" rating given on Wednesday, October 18 by FBR Capital. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company's stock worth $727,308,000 after buying an additional 153,908 shares during the period. On Wednesday, September 7 the stock rating was maintained by Jefferies with "Buy".
Since May 26, 2017, it had 0 buys, and 1 sale for $200,387 activity. Winningham Rick E sold 5,000 shares worth $750,000.
Investors sentiment increased to 1.39 in Q2 2017. Its up 0.44, from 0.95 in 2017Q1. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/22/jazz-pharmaceuticals-plc-jazz-svp-iain-mcgill-sells-8000-shares-of-stock.html. 51 funds opened positions while 102 raised stakes. Raymond James & Associate owns 0.01% invested in Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ) for 28,652 shares. Gotham Asset Ltd owns 30,308 shares. Jazz Pharmaceuticals PLC has a 1-year low of $99.28 and a 1-year high of $163.75. FMR LLC increased its holdings in shares of Jazz Pharmaceuticals PLC by 11.4% in the second quarter. Analysts forecast EPS of $2.73, up exactly $0.82 or 42.93 % from 2014's $1.91 EPS. Virginia Retirement Et Al holds 13,300 shares. Magnetar Lc accumulated 4,347 shares. The United Kingdom-based Ahl Partners Llp has invested 0.04% in Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ). 235,800 are owned by Strs Ohio. Finally, BMO Capital Markets restated a "buy" rating and issued a $196.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, September 20th. It also reduced its holding in Gigamon Inc (NYSE:GIMO) by 64,329 shares in the quarter, leaving it with 149,033 shares, and cut its stake in Evolent Health.
More recent Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ) news were published by: Prnewswire.com which released: "Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results" on February 28, 2017. Benzinga.com's news article titled: "UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma" with publication date: April 06, 2017 was also an interesting one.
Since June 1, 2017, it had 0 insider buys, and 2 insider sales for $780,130 activity. Moreover, Perceptive Ltd has 0.67% invested in Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ) for 85,572 shares.
- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.